Search

Your search keyword '"Parra Cuentas, Edwin R."' showing total 21 results
Start Over Author "Parra Cuentas, Edwin R."
21 results on '"Parra Cuentas, Edwin R."'

1. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Author

Skoulidis, Ferdinandos, Araujo, Haniel A., Do, Minh Truong, Qian, Yu, Sun, Xin, Cobo, Ana Galan, Le, John T., Montesion, Meagan, Palmer, Rachael, Jahchan, Nadine, Juan, Joseph M., Min, Chengyin, Yu, Yi, Pan, Xuewen, Arbour, Kathryn C., Vokes, Natalie, Schmidt, Stephanie T., Molkentine, David, Owen, Dwight H., Memmott, Regan, Patil, Pradnya D., Marmarelis, Melina E., Awad, Mark M., Murray, Joseph C., Hellyer, Jessica A., Gainor, Justin F., Dimou, Anastasios, Bestvina, Christine M., Shu, Catherine A., Riess, Jonathan W., Blakely, Collin M., Pecot, Chad V., Mezquita, Laura, Tabbó, Fabrizio, Scheffler, Matthias, Digumarthy, Subba, Mooradian, Meghan J., Sacher, Adrian G., Lau, Sally C. M., Saltos, Andreas N., Rotow, Julia, Johnson, Rocio Perez, Liu, Corinne, Stewart, Tyler, Goldberg, Sarah B., Killam, Jonathan, Walther, Zenta, Schalper, Kurt, Davies, Kurtis D., Woodcock, Mark G., Anagnostou, Valsamo, Marrone, Kristen A., Forde, Patrick M., Ricciuti, Biagio, Venkatraman, Deepti, Van Allen, Eliezer M., Cummings, Amy L., Goldman, Jonathan W., Shaish, Hiram, Kier, Melanie, Katz, Sharyn, Aggarwal, Charu, Ni, Ying, Azok, Joseph T., Segal, Jeremy, Ritterhouse, Lauren, Neal, Joel W., Lacroix, Ludovic, Elamin, Yasir Y., Negrao, Marcelo V., Le, Xiuning, Lam, Vincent K., Lewis, Whitney E., Kemp, Haley N., Carter, Brett, Roth, Jack A., Swisher, Stephen, Lee, Richard, Zhou, Teng, Poteete, Alissa, Kong, Yifan, Takehara, Tomohiro, Paula, Alvaro Guimaraes, Parra Cuentas, Edwin R., Behrens, Carmen, Wistuba, Ignacio I., Zhang, Jianjun, Blumenschein, George R., Gay, Carl, Byers, Lauren A., Gibbons, Don L., Tsao, Anne, Lee, J. Jack, Bivona, Trever G., Camidge, D. Ross, Gray, Jhannelle E., Lieghl, Natasha, Levy, Benjamin, Brahmer, Julie R., Garassino, Marina C., Gandara, David R., Garon, Edward B., Rizvi, Naiyer A., Scagliotti, Giorgio Vittorio, Wolf, Jürgen, Planchard, David, Besse, Benjamin, Herbst, Roy S., Wakelee, Heather A., Pennell, Nathan A., Shaw, Alice T., Jänne, Pasi A., Carbone, David P., Hellmann, Matthew D., Rudin, Charles M., Albacker, Lee, Mann, Helen, Zhu, Zhou, Lai, Zhongwu, Stewart, Ross, Peters, Solange, Johnson, Melissa L., Wong, Kwok K., Huang, Alan, Winslow, Monte M., Rosen, Michael J., Winters, Ian P., Papadimitrakopoulou, Vassiliki A., Cascone, Tina, Jewsbury, Philip, and Heymach, John V.

Published
2024
Full Text
View/download PDF

2. Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk

Author

Almekinders, Mathilde M., Bismeijer, Tycho, Kumar, Tapsi, Yang, Fei, Thijssen, Bram, van der Linden, Rianne, van Rooijen, Charlotte, Vonk, Shiva, Sun, Baohua, Parra Cuentas, Edwin R., Wistuba, Ignacio I., Krishnamurthy, Savitri, Visser, Lindy L., Seignette, Iris M., Hofland, Ingrid, Sanders, Joyce, Broeks, Annegien, Love, Jason K., Menegaz, Brian, Wessels, Lodewyk, Thompson, Alastair M., de Visser, Karin E., Hooijberg, Erik, Lips, Esther, Futreal, Andrew, and Wesseling, Jelle

Published
2022
Full Text
View/download PDF

3. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC

Author

Gaudreau, Pierre-Olivier, Negrao, Marcelo V., Mitchell, Kyle G., Reuben, Alexandre, Corsini, Erin M., Li, Jun, Karpinets, Tatiana V., Wang, Qi, Diao, Lixia, Wang, Jing, Federico, Lorenzo, Parra-Cuentas, Edwin R., Khairullah, Roohussaba, Behrens, Carmen, Correa, Arlene M., Gomez, Daniel, Little, Latasha, Gumbs, Curtis, Kadara, Humam N., Fujimoto, Junya, McGrail, Daniel J., Vaporciyan, Ara A., Swisher, Stephen G., Walsh, Garrett, Antonoff, Mara B., Weissferdt, Annikka, Tran, Hai, Roarty, Emily, Haymaker, Cara, Bernatchez, Chantale, Zhang, Jianhua, Futreal, P. Andrew, Wistuba, Ignacio I., Cascone, Tina, Heymach, John V., Sepesi, Boris, Zhang, Jianjun, and Gibbons, Don L.

Published
2021
Full Text
View/download PDF

4. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

Author

Koyama, Shohei, Akbay, Esra A, Li, Yvonne Y, Aref, Amir R, Skoulidis, Ferdinandos, Herter-Sprie, Grit S, Buczkowski, Kevin A, Liu, Yan, Awad, Mark M, Denning, Warren L, Diao, Lixia, Wang, Jing, Parra-Cuentas, Edwin R, Wistuba, Ignacio I, Soucheray, Margaret, Thai, Tran, Asahina, Hajime, Kitajima, Shunsuke, Altabef, Abigail, Cavanaugh, Jillian D, Rhee, Kevin, Gao, Peng, Zhang, Haikuo, Fecci, Peter E, Shimamura, Takeshi, Hellmann, Matthew D, Heymach, John V, Hodi, F Stephen, Freeman, Gordon J, Barbie, David A, Dranoff, Glenn, Hammerman, Peter S, and Wong, Kwok-Kin

Subjects
Clinical Research, Lung, Cancer, Lung Cancer, 5.1 Pharmaceuticals, 2.1 Biological and endogenous factors, Aetiology, Development of treatments and therapeutic interventions, AMP-Activated Protein Kinase Kinases, AMP-Activated Protein Kinases, Animals, B7-H1 Antigen, Cytokines, Humans, Lung Neoplasms, Lymphocytes, Tumor-Infiltrating, Mice, Mutation, Neutrophil Infiltration, Protein Serine-Threonine Kinases, T-Lymphocytes, Tumor Microenvironment, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

STK11/LKB1 is among the most commonly inactivated tumor suppressors in non-small cell lung cancer (NSCLC), especially in tumors harboring KRAS mutations. Many oncogenes promote immune escape, undermining the effectiveness of immunotherapies, but it is unclear whether the inactivation of tumor suppressor genes, such as STK11/LKB1, exerts similar effects. In this study, we investigated the consequences of STK11/LKB1 loss on the immune microenvironment in a mouse model of KRAS-driven NSCLC. Genetic ablation of STK11/LKB1 resulted in accumulation of neutrophils with T-cell-suppressive effects, along with a corresponding increase in the expression of T-cell exhaustion markers and tumor-promoting cytokines. The number of tumor-infiltrating lymphocytes was also reduced in LKB1-deficient mouse and human tumors. Furthermore, STK11/LKB1-inactivating mutations were associated with reduced expression of PD-1 ligand PD-L1 in mouse and patient tumors as well as in tumor-derived cell lines. Consistent with these results, PD-1-targeting antibodies were ineffective against Lkb1-deficient tumors. In contrast, treating Lkb1-deficient mice with an IL6-neutralizing antibody or a neutrophil-depleting antibody yielded therapeutic benefits associated with reduced neutrophil accumulation and proinflammatory cytokine expression. Our findings illustrate how tumor suppressor mutations can modulate the immune milieu of the tumor microenvironment, and they offer specific implications for addressing STK11/LKB1-mutated tumors with PD-1-targeting antibody therapies.

Published
2016

5. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study

Author

Gordon, Max J., primary, Feng, Lei, additional, Strati, Paolo, additional, Lee, Hun Ju, additional, Hagemeister, Fredrick B., additional, Westin, Jason R., additional, Samaniego, Felipe, additional, Marques‐Piubelli, Mario L., additional, Vega Vazquez, Francisco, additional, Parra Cuentas, Edwin R., additional, Solis‐Soto, Luisa M., additional, Ma, Wencai, additional, Wang, Jing, additional, Claret, Linda, additional, Averill, Barbara, additional, Ibanez, Karina, additional, Fayad, Luis E., additional, Flowers, Christopher R., additional, Green, Michael R., additional, Davis, R. Eric, additional, Neelapu, Sattva S., additional, Fowler, Nathan H., additional, and Nastoupil, Loretta J., additional

Published
2023
Full Text
View/download PDF

6. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.

Author

Gordon, Max J., Feng, Lei, Strati, Paolo, Lee, Hun Ju, Hagemeister, Fredrick B., Westin, Jason R., Samaniego, Felipe, Marques‐Piubelli, Mario L., Vega Vazquez, Francisco, Parra Cuentas, Edwin R., Solis‐Soto, Luisa M., Ma, Wencai, Wang, Jing, Claret, Linda, Averill, Barbara, Ibanez, Karina, Fayad, Luis E., Flowers, Christopher R., Green, Michael R., and Davis, R. Eric

Subjects
MUCOSA-associated lymphoid tissue lymphoma, LENALIDOMIDE, BRUTON tyrosine kinase, RITUXIMAB, FOLLICULAR lymphoma
Abstract

Background: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent non‐Hodgkin lymphomas (iNHL). Median survival for iNHL is approximately 20 years. Because standard treatments are not curative, patients often receive multiple lines of therapy with associated toxicity—rationally designed, combination therapies with curative potential are needed. The immunomodulatory drug lenalidomide was evaluated in combination with rituximab for the frontline treatment of FL in the phase 3 RELEVANCE study. Ibrutinib, an oral Bruton tyrosine kinase inhibitor, is active in NHL and was evaluated in combination with lenalidomide, rituximab, and ibrutinib (IRR) in a phase 1 study. Methods: The authors conducted an open‐label, phase 2 clinical trial of IRR for previously untreated FL and MZL. The primary end point was progression‐free survival (PFS) at 24 months. Results: This study included 48 participants with previously untreated FL grade 1–3a (N = 38), or MZL (N = 10). Participants received 12, 28‐day cycles of lenalidomide (15 mg, days 1–21 cycle 1; 20 mg, cycles 2–12), rituximab (375 mg/m2 weekly in cycle 1; day 1 cycles 2‐12), and ibrutinib 560 mg daily. With a median follow‐up of 65.3 months, the estimated PFS at 24 months was 78.8% (95% confidence interval [CI], 68.0%–91.4%) and 60‐month PFS was 59.7% (95% CI, 46.6%–76.4%). One death occurred unrelated to disease progression. Grade 3–4 adverse events were observed in 64.6%, including 50% with grade 3–4 rash. Conclusions: IRR is highly active as frontline therapy for FL and MZL. Compared to historical results with lenalidomide and rituximab, PFS is similar with higher grade 3–4 toxicity, particularly rash. The study was registered with ClinicalTrials.gov (NCT02532257). After 5 years of follow‐up from a phase 2 clinical trial of ibrutinib, lenalidomide, and rituximab in previously untreated patients with follicular and marginal zone lymphoma, the 5‐year progression‐free survival rate was 59.7% and the overall survival rate was 97.9%. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Supplementary Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

Author

Raghav, Kanwal, primary, Liu, Suyu, primary, Overman, Michael J., primary, Willett, Anneleis F., primary, Knafl, Mark, primary, Fu, Szu-Chin, primary, Malpica, Anais, primary, Prasad, Seema, primary, Royal, Richard E., primary, Scally, Christopher P., primary, Mansfield, Paul F., primary, Wistuba, Ignacio I., primary, Futreal, Andrew P., primary, Maru, Dipen M., primary, Solis Soto, Luisa M., primary, Parra Cuentas, Edwin R., primary, Chen, Honglei, primary, Villalobos, Pamela, primary, Verma, Anuj, primary, Mahvash, Armeen, primary, Hwu, Patrick, primary, Cortazar, Patricia, primary, McKenna, Edward, primary, Yun, Cindy, primary, Dervin, Shannon, primary, Schulze, Katja, primary, Darbonne, Walter C., primary, Morani, Ajaykumar C., primary, Kopetz, Scott, primary, Fournier, Keith F., primary, Woodman, Scott E., primary, Yao, James C., primary, Varadhachary, Gauri R., primary, and Halperin, Daniel M., primary

Published
2023
Full Text
View/download PDF

8. Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

Author

Raghav, Kanwal, primary, Liu, Suyu, primary, Overman, Michael J., primary, Willett, Anneleis F., primary, Knafl, Mark, primary, Fu, Szu-Chin, primary, Malpica, Anais, primary, Prasad, Seema, primary, Royal, Richard E., primary, Scally, Christopher P., primary, Mansfield, Paul F., primary, Wistuba, Ignacio I., primary, Futreal, Andrew P., primary, Maru, Dipen M., primary, Solis Soto, Luisa M., primary, Parra Cuentas, Edwin R., primary, Chen, Honglei, primary, Villalobos, Pamela, primary, Verma, Anuj, primary, Mahvash, Armeen, primary, Hwu, Patrick, primary, Cortazar, Patricia, primary, McKenna, Edward, primary, Yun, Cindy, primary, Dervin, Shannon, primary, Schulze, Katja, primary, Darbonne, Walter C., primary, Morani, Ajaykumar C., primary, Kopetz, Scott, primary, Fournier, Keith F., primary, Woodman, Scott E., primary, Yao, James C., primary, Varadhachary, Gauri R., primary, and Halperin, Daniel M., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Protocol from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

Author

Raghav, Kanwal, primary, Liu, Suyu, primary, Overman, Michael J., primary, Willett, Anneleis F., primary, Knafl, Mark, primary, Fu, Szu-Chin, primary, Malpica, Anais, primary, Prasad, Seema, primary, Royal, Richard E., primary, Scally, Christopher P., primary, Mansfield, Paul F., primary, Wistuba, Ignacio I., primary, Futreal, Andrew P., primary, Maru, Dipen M., primary, Solis Soto, Luisa M., primary, Parra Cuentas, Edwin R., primary, Chen, Honglei, primary, Villalobos, Pamela, primary, Verma, Anuj, primary, Mahvash, Armeen, primary, Hwu, Patrick, primary, Cortazar, Patricia, primary, McKenna, Edward, primary, Yun, Cindy, primary, Dervin, Shannon, primary, Schulze, Katja, primary, Darbonne, Walter C., primary, Morani, Ajaykumar C., primary, Kopetz, Scott, primary, Fournier, Keith F., primary, Woodman, Scott E., primary, Yao, James C., primary, Varadhachary, Gauri R., primary, and Halperin, Daniel M., primary

Published
2023
Full Text
View/download PDF

10. Supplementary methods from STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

Author

Koyama, Shohei, primary, Akbay, Esra A., primary, Li, Yvonne Y., primary, Aref, Amir R., primary, Skoulidis, Ferdinandos, primary, Herter-Sprie, Grit S., primary, Buczkowski, Kevin A., primary, Liu, Yan, primary, Awad, Mark M., primary, Denning, Warren L., primary, Diao, Lixia, primary, Wang, Jing, primary, Parra-Cuentas, Edwin R., primary, Wistuba, Ignacio I., primary, Soucheray, Margaret, primary, Thai, Tran, primary, Asahina, Hajime, primary, Kitajima, Shunsuke, primary, Altabef, Abigail, primary, Cavanaugh, Jillian D., primary, Rhee, Kevin, primary, Gao, Peng, primary, Zhang, Haikuo, primary, Fecci, Peter E., primary, Shimamura, Takeshi, primary, Hellmann, Matthew D., primary, Heymach, John V., primary, Hodi, F. Stephen, primary, Freeman, Gordon J., primary, Barbie, David A., primary, Dranoff, Glenn, primary, Hammerman, Peter S., primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

11. Supplementary method figure from STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

Author

Koyama, Shohei, primary, Akbay, Esra A., primary, Li, Yvonne Y., primary, Aref, Amir R., primary, Skoulidis, Ferdinandos, primary, Herter-Sprie, Grit S., primary, Buczkowski, Kevin A., primary, Liu, Yan, primary, Awad, Mark M., primary, Denning, Warren L., primary, Diao, Lixia, primary, Wang, Jing, primary, Parra-Cuentas, Edwin R., primary, Wistuba, Ignacio I., primary, Soucheray, Margaret, primary, Thai, Tran, primary, Asahina, Hajime, primary, Kitajima, Shunsuke, primary, Altabef, Abigail, primary, Cavanaugh, Jillian D., primary, Rhee, Kevin, primary, Gao, Peng, primary, Zhang, Haikuo, primary, Fecci, Peter E., primary, Shimamura, Takeshi, primary, Hellmann, Matthew D., primary, Heymach, John V., primary, Hodi, F. Stephen, primary, Freeman, Gordon J., primary, Barbie, David A., primary, Dranoff, Glenn, primary, Hammerman, Peter S., primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

12. Supplemental Figures from STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

Author

Koyama, Shohei, primary, Akbay, Esra A., primary, Li, Yvonne Y., primary, Aref, Amir R., primary, Skoulidis, Ferdinandos, primary, Herter-Sprie, Grit S., primary, Buczkowski, Kevin A., primary, Liu, Yan, primary, Awad, Mark M., primary, Denning, Warren L., primary, Diao, Lixia, primary, Wang, Jing, primary, Parra-Cuentas, Edwin R., primary, Wistuba, Ignacio I., primary, Soucheray, Margaret, primary, Thai, Tran, primary, Asahina, Hajime, primary, Kitajima, Shunsuke, primary, Altabef, Abigail, primary, Cavanaugh, Jillian D., primary, Rhee, Kevin, primary, Gao, Peng, primary, Zhang, Haikuo, primary, Fecci, Peter E., primary, Shimamura, Takeshi, primary, Hellmann, Matthew D., primary, Heymach, John V., primary, Hodi, F. Stephen, primary, Freeman, Gordon J., primary, Barbie, David A., primary, Dranoff, Glenn, primary, Hammerman, Peter S., primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

13. Supplementary figure legends from STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

Author

Koyama, Shohei, primary, Akbay, Esra A., primary, Li, Yvonne Y., primary, Aref, Amir R., primary, Skoulidis, Ferdinandos, primary, Herter-Sprie, Grit S., primary, Buczkowski, Kevin A., primary, Liu, Yan, primary, Awad, Mark M., primary, Denning, Warren L., primary, Diao, Lixia, primary, Wang, Jing, primary, Parra-Cuentas, Edwin R., primary, Wistuba, Ignacio I., primary, Soucheray, Margaret, primary, Thai, Tran, primary, Asahina, Hajime, primary, Kitajima, Shunsuke, primary, Altabef, Abigail, primary, Cavanaugh, Jillian D., primary, Rhee, Kevin, primary, Gao, Peng, primary, Zhang, Haikuo, primary, Fecci, Peter E., primary, Shimamura, Takeshi, primary, Hellmann, Matthew D., primary, Heymach, John V., primary, Hodi, F. Stephen, primary, Freeman, Gordon J., primary, Barbie, David A., primary, Dranoff, Glenn, primary, Hammerman, Peter S., primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

14. Data from STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

Author

Koyama, Shohei, primary, Akbay, Esra A., primary, Li, Yvonne Y., primary, Aref, Amir R., primary, Skoulidis, Ferdinandos, primary, Herter-Sprie, Grit S., primary, Buczkowski, Kevin A., primary, Liu, Yan, primary, Awad, Mark M., primary, Denning, Warren L., primary, Diao, Lixia, primary, Wang, Jing, primary, Parra-Cuentas, Edwin R., primary, Wistuba, Ignacio I., primary, Soucheray, Margaret, primary, Thai, Tran, primary, Asahina, Hajime, primary, Kitajima, Shunsuke, primary, Altabef, Abigail, primary, Cavanaugh, Jillian D., primary, Rhee, Kevin, primary, Gao, Peng, primary, Zhang, Haikuo, primary, Fecci, Peter E., primary, Shimamura, Takeshi, primary, Hellmann, Matthew D., primary, Heymach, John V., primary, Hodi, F. Stephen, primary, Freeman, Gordon J., primary, Barbie, David A., primary, Dranoff, Glenn, primary, Hammerman, Peter S., primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

15. The Th17 pathway in the peripheral lung microenvironment interacts with expression of collagen V in the late state of experimental pulmonary fibrosis

Author

Fabro, Alexandre T., da Silva, Pedro H.R.Q., Zocolaro, William S., de Almeida, Mozar S., Rangel, Maristela P., de Oliveira, Cristiano C., Minatel, Igor O., Prando, Erika d.C., Rainho, Claudia A., Teodoro, Walcy R., Velosa, Ana P.P., Saber, Alexandre M.A., Parra-Cuentas, Edwin R., Popper, Helmut H., and Capelozzi, Vera L.

Published
2015
Full Text
View/download PDF

16. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab

Author

Marques-Piubelli, Mario L., primary, Parra Cuentas, Edwin R., additional, Feng, Lei, additional, Solis Soto, Luisa, additional, Gallardo, Mariana, additional, Gouni, Sushanth, additional, Samaniego, Felipe, additional, Noorani, Mansoor, additional, Hagemeister, Fredrick B., additional, Westin, Jason R, additional, Lee, Hun Ju, additional, Rodriguez, Maria A., additional, Neelapu, Sattva S., additional, Gunther, Jillian R., additional, Fowler, Nathan H, additional, Flowers, Christopher R., additional, Wistuba, Ignacio I, additional, Nastoupil, Loretta J., additional, Vega, Francisco, additional, and Strati, Paolo, additional

Published
2022
Full Text
View/download PDF

17. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

Author

Raghav, Kanwal, primary, Liu, Suyu, additional, Overman, Michael J., additional, Willett, Anneleis F., additional, Knafl, Mark, additional, Fu, Szu-Chin, additional, Malpica, Anais, additional, Prasad, Seema, additional, Royal, Richard E., additional, Scally, Christopher P., additional, Mansfield, Paul F., additional, Wistuba, Ignacio I., additional, Futreal, Andrew P., additional, Maru, Dipen M., additional, Solis Soto, Luisa M., additional, Parra Cuentas, Edwin R., additional, Chen, Honglei, additional, Villalobos, Pamela, additional, Verma, Anuj, additional, Mahvash, Armeen, additional, Hwu, Patrick, additional, Cortazar, Patricia, additional, McKenna, Edward, additional, Yun, Cindy, additional, Dervin, Shannon, additional, Schulze, Katja, additional, Darbonne, Walter C., additional, Morani, Ajaykumar C., additional, Kopetz, Scott, additional, Fournier, Keith F., additional, Woodman, Scott E., additional, Yao, James C., additional, Varadhachary, Gauri R., additional, and Halperin, Daniel M., additional

Published
2021
Full Text
View/download PDF

18. Impact of co-mutations on the immune microenvironment of KRAS-mutant lung adenocarcinoma

Author

Skoulidis, Ferdinandos, primary, Denning, Warren, additional, Diao, Lixia, additional, Tong, Pan, additional, Fan, You Hong, additional, Papadimitrakopoulou, Vassiliki, additional, Izzo, Julie, additional, Behrens, Carmen, additional, Kadara, Humam, additional, Parra Cuentas, Edwin R., additional, Canales, Jaime Rodriguez, additional, Wang, Jing, additional, Byers, Lauren A., additional, Wistuba, Ignacio I., additional, and Heymach, John V., additional

Published
2016
Full Text
View/download PDF

20. Degree of endothelium injury promotes fibroelastogenesis in experimental acute lung injury

Author

Chao, Mônica C.M., primary, Garcia, Cristiane S.N.B., additional, de Oliveira, Mariana B.G., additional, Santos, Raquel S., additional, Lucas, Isabela H., additional, Silva, Pedro L., additional, Vieira-Abreu, Adriana, additional, de Castro-Faria-Neto, Hugo C., additional, Parra-Cuentas, Edwin R., additional, Capelozzi, Vera L., additional, Pelosi, Paolo, additional, and Rocco, Patricia R.M., additional

Published
2010
Full Text
View/download PDF

21. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.

Author

Shohei Koyama, Akbay, Esra A., Y. Li, Yvonne, Aref, Amir R., Skoulidis, Ferdinandos, Herter-Sprie, Grit S., Buczkowski, Kevin A., Yan Liu, Awad, Mark M., Denning, Warren L., Lixia Diao, Jing Wang, Parra-Cuentas, Edwin R., Wistuba, Ignacio I., Soucheray, Margaret, Tran Thai, Hajime Asahina, Shunsuke Kitajima, Altabef, Abigail, and Cavanaugh, Jillian D.

Subjects
*LUNG tumors, *PROTEIN deficiency, *NEUTROPHILS, *CYTOKINES, *T cells, *PHYSIOLOGY
Abstract

STK11/LKB1 is among the most commonly inactivated tumor suppressors in non--small cell lung cancer (NSCLC), especially in tumors harboring KRAS mutations. Many oncogenes promote immune escape, undermining the effectiveness of immunotherapies, but it is unclear whether the inactivation of tumor suppressor genes, such as STK11/LKB1, exerts similar effects. In this study, we investigated the consequences of STK11/LKB1 loss on the immune microenvironment in a mouse model of KRAS-driven NSCLC. Genetic ablation of STK11/LKB1 resulted in accumulation of neutrophilswith T-cell--suppressive effects, along with a corresponding increase in the expression of T-cell exhaustion markers and tumorpromoting cytokines. The number of tumor-infiltrating lymphocytes was also reduced in LKB1-deficient mouse and human tumors. Furthermore, STK11/LKB1--inactivating mutations were associated with reduced expression ofPD-1 ligand PD-L1 inmouse and patient tumors as well as in tumor-derived cell lines.Consistent with these results, PD-1--targeting antibodies were ineffective against Lkb1-deficient tumors. In contrast, treating Lkb1-deficient mice with an IL6-neutralizing antibody or a neutrophil-depleting antibody yielded therapeutic benefits associated with reduced neutrophil accumulation and proinflammatory cytokine expression. Our findings illustrate how tumor suppressor mutations can modulate the immunemilieu of the tumormicroenvironment, and they offer specific implications for addressing STK11/LKB1--mutated tumors withPD-1--targeting antibody therapies. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results